<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To determine if maintenance rituximab (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>) after standard chemotherapy improves progression-free survival (PFS) in advanced-stage indolent <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Patients with stage III-IV indolent <z:hpo ids='HP_0002665'>lymphoma</z:hpo> with responding or stable disease after <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, and <z:chebi fb="0" ids="8382">prednisone</z:chebi> (CVP) chemotherapy were stratified by initial <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden, <z:e sem="disease" ids="C0543478" disease_type="Neoplastic Process" abbrv="">residual disease</z:e> after CVP (minimal or gross), and histology, and randomly assigned to observation (OBS) or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> 375 mg/m(2) once per week for 4 weeks every 6 months for 2 years </plain></SENT>
<SENT sid="2" pm="."><plain>PFS was the primary end point </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Three hundred eleven (282 with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>) evaluable patients who received CVP were randomly assigned to OBS (n = 158) or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> (n = 153) </plain></SENT>
<SENT sid="4" pm="."><plain>Best response improved in 22% <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> versus 7% OBS patients (P = .00006) </plain></SENT>
<SENT sid="5" pm="."><plain>Toxicity was minimal in both study arms </plain></SENT>
<SENT sid="6" pm="."><plain>Three-year PFS after random assignment was 68% <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> versus 33% OBS (hazard ratio [HR] = 0.4; P = 4.4 x 10(-10) [<z:hpo ids='HP_0000001'>all</z:hpo> patients]) and 64% <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> v 33% OBS (HR = 0.4; P = 9.2 x 10(-8) [patients with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>]) </plain></SENT>
<SENT sid="7" pm="."><plain>There was an advantage for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> regardless of Follicular <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> International Prognostic Index score, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden, <z:e sem="disease" ids="C0543478" disease_type="Neoplastic Process" abbrv="">residual disease</z:e>, or histology </plain></SENT>
<SENT sid="8" pm="."><plain>In multivariate analysis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> patients, minimal disease after CVP was a favorable prognostic factor </plain></SENT>
<SENT sid="9" pm="."><plain>OS at 3 years was 92% <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> versus 86% OBS (HR = 0.6; log-rank one-sided P = .05) and, among patients with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, OS was 91% <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> versus 86% (HR = 0.6; log-rank one-sided P = .08) </plain></SENT>
<SENT sid="10" pm="."><plain>A trend favoring <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> was observed among patients with high <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden (log-rank one-sided P = .03) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: The E1496 study provides the first phase III data in untreated indolent <z:hpo ids='HP_0002665'>lymphoma</z:hpo> that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> after chemotherapy significantly prolongs PFS </plain></SENT>
</text></document>